Randomised comparison of partial liquid ventilation, nebulised perfluorocarbon, porcine surfactant, artificial surfactant, and combined treatments on oxygenation, lung mechanics, and survival in rabbits after saline lung lavage

Kelly, K.P.; Stenson, B.J.; Drummond, G.B.
October 2000
Intensive Care Medicine;Oct2000, Vol. 26 Issue 10, p1523
Academic Journal
Objective: To compare gas exchange, lung mechanics, and survival to 12 h in surfactant-depleted lung-injured rabbits, treated with partial liquid ventilation (PLV) with perfluorocarbon, nebulised perfluorocarbon, and porcine or artificial surfactant. Design: Prospective randomised controlled study. Setting: Animal laboratory, University of Edinburgh, UK. Subjects: Eighty-two adult female New Zealand white rabbits with surfactant deficiency and acute lung injury induced by repeated saline lavage. Interventions: Animals were randomised to one of seven treatments: (a) control (n=20); (b) PLV with perfluorocarbon PF 5080 (n=12); (c) nebulised PF 5080 (n=10); (d) artificial surfactant (n=10); (e) porcine surfactant (n=10); (f) artificial surfactant+PLV (n=10); (g) porcine surfactant+PLV (n=10). Measurements and main results: Arterial blood gases and dynamic compliance (Cdyn) were measured hourly until 12 h. Oxygenation was improved by PLV, porcine surfactant, porcine surfactant+PLV and artificial surfactant+PLV. Cdyn improved after treatment with PLV, porcine surfactant and PLV+porcine surfactant. Survival was greater with PLV and artificial surfactant+PLV. Neither nebulised PF 5080 nor artificial surfactant had a detectable effect. Conclusions: PLV, porcine surfactant and combinations of surfactant with PLV improved oxygenation, Cdyn and survival, but none was clearly superior to the others.


Related Articles

  • Effects of positive end-expiratory pressure on the sigmoid equation in experimental acute lung injury. Bayle, Frederique; Guerin, Claude; Viale, Jean-Paul; Richard, Jean-Christophe; Annat, Guy // Intensive Care Medicine;Nov2004, Vol. 30 Issue 11, p2121 

    Objectives: To describe inflation and deflation volume-pressure (V-P) curves of the respiratory system by the sigmoidal equation at different levels of positive end-expiratory pressure (PEEP) in acute lung injury.Design: Experimental study.Setting:...

  • The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy. Charles L. Densmore // Current Cancer Drug Targets;Aug2003, Vol. 3 Issue 4, p275 

    The long-term survival of lung cancer patients treated with conventional therapies (surgery, radiation therapy and chemotherapy) remains poor and has changed little in decades. The need for novel approaches remains high and gene therapy holds promise in this area. A number of genes have been...

  • Indacaterol improves clinical benefits for COPD patients.  // British Journal of Hospital Medicine (17508460);Nov2011, Vol. 72 Issue 11, p609 

    The article reports the INTENSITY study, which compared Onbrez Breezhaler with Spiriva HandiHaler, and revealed that indacaterol is more beneficial than tiotropium for patients with chronic obstructive pulmonary disease (COPD).

  • Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. McLachlan, G; Davidson, H; Holder, E; Davies, L A; Pringle, I A; Sumner-Jones, S G; Baker, A; Tennant, P; Gordon, C; Vrettou, C; Blundell, R; Hyndman, L; Stevenson, B; Wilson, A; Doherty, A; Shaw, D J; Coles, R L; Painter, H; Cheng, S H; Scheule, R K // Gene Therapy;Oct2011, Vol. 18 Issue 10, p996 

    We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GTAs) for cystic fibrosis (CF) gene therapy. Here, we report the use of a large animal model to assess three non-viral GTAs: 25 kDa-branched polyethyleneimine (PEI), the cationic liposome (GL67A)...

  • Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis. Alhanout, Kamel; Brunel, Jean Michel; Dubus, Jean Christophe; Rolain, Jean Marc; Andrieu, Véronique // Journal of Antimicrobial Chemotherapy (JAC);Dec2011, Vol. 66 Issue 12, p2797 

    Objectives We evaluated the suitability of an aminosterol derivative (ASD), possessing interesting in vitro antimicrobial activities against various resistant pathogens involved in lung infections of cystic fibrosis patients, for aerosol drug delivery. Methods The suitability of 2 and 10 mg/mL...

  • Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers. Chand Khanna; David M. Vail // Current Cancer Drug Targets;Aug2003, Vol. 3 Issue 4, p265 

    Pet dogs with naturally occurring cancers offer a novel opportunity for the study of both cancer biology and therapy. The following review will provide the rationale for the use of these spontaneous cancer models in translational research, particularly in the development of anticancer aerosols....

  • Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Amirav I; Balanov I; Gorenberg M; Groshar D; Luder A S // Archives of Disease in Childhood;Aug2003, Vol. 88 Issue 8, p719 

    BACKGROUND: Small volume nebulisers (SVNs) with masks commonly provide aerosol therapy for infants with lung diseases. However, infants and toddlers are often disturbed by and thus reject masks. AIMS: To compare the lung deposition efficiency of the "usual" SVN aerosol mask and a prototype hood...

  • Nebulizers vs. MDIs with spacers for COPD or asthma. Miller, Karl // American Family Physician;6/1/1998, Vol. 57 Issue 11, p2836 

    Presents information on the nebulizer treatment which is recommended for the management of patients with acute exacerbations of chronic obstructive pulmonary diseases (COPD) or asthma. Requirements of the nebulizer treatment; Rating of symptom response after the treatment.

  • Pharmaceutical aerosols for the treatment and prevention of Tuberculosis. Hanif, Shumaila N. M.; Garcia-Contreras, Lucila // Frontiers in Cellular & Infection Microbiology;Sep2012, Vol. 2, p1 

    Historically, pharmaceutical aerosols have been employed for the treatment of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the past decades their use has been expanded to treat lung infections associated with cystic fibrosis and other respiratory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics